← Back to Clinical Trials
Recruiting Phase 1 NCT07216781

Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans

Trial Parameters

Condition Healthy Adults
Sponsor Minicircle
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 24
Sex ALL
Min Age 23 Years
Max Age 90 Years
Start Date 2025-10-06
Completion 2026-08
Interventions
Injectable Plasmid Klotho Gene Therapy

Brief Summary

The purpose of this study is to investigate the safety and efficacy of a gene therapy for Klotho, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of the Klotho gene therapy.

Eligibility Criteria

Inclusion Criteria: * Participant is open to morphological change * If female, participant agrees to maintain contraception * If female, participant agrees to take a pregnancy test * If female, participant agrees to a pregnancy waiver Exclusion Criteria: * Women of childbearing potential who are unwilling or unable to use effective contraception for the duration of the study * History of cancer diagnosis * Preexisting medical issues that may be exacerbated by the treatment * Has received any gene therapy within the past 12 months * Unwilling or unable to provide written informed consent

Related Trials